Please ensure Javascript is enabled for purposes of website accessibility

Acceleron Shares Surge as Its Hypertension Drug Meets Trial Endpoints

By Mark Prvulovic - Updated Jan 27, 2020 at 8:40PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The new drug treats high blood pressure in the lungs.

Shares of Acceleron Pharma (XLRN) shot up significantly in after-hours trading on Monday when the company announced positive results for its drug to treat pulmonary arterial hypertension (PAH). A phase 2 clinical trial of Acceleron's drug candidate, sotatercept, met both the primary and secondary endpoints of the trial.

More specifically, the study in question found that there was a significant reduction in pulmonary vascular resistance, the amount of blood pressure in the arteries that provide blood to the lungs, in comparison to the placebo.

A close-up of a persons lungs and the airway tracts that encompass it.

Image source: Getty Images.

CEO Habib Dable said: "We're thrilled to report such positive top-line results from the PULSAR trial. PAH is a debilitating disease of high unmet medical need, so we're encouraged by these data that signal that sotatercept could deliver added benefit to patients." 

A rare disease

Pulmonary arterial hypertension is a condition in which a patient has high blood pressure in the lungs. This means that the part of the heart responsible for pumping oxygen to the lungs, the right ventricle, has to work even harder to do its job. Eventually, this can lead to right ventricular failure and death.

At the moment, there are no drugs that specifically treat PAH. General treatments for high blood pressure, such as calcium channel blockers that help lower blood pressure, can help patients manage their condition. The disease remains quite rare, with anywhere between 10 to 50 cases of PAH occurring per million people.

Shares of Acceleron had jumped 66% in after-hours trading on Monday. The biotech company has five drug candidates in its pipeline, with one of them -- a transfusion-dependent beta thalassemia treatment -- having already been approved.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Acceleron Pharma Stock Quote
Acceleron Pharma

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.